On Thursday, the Centers for Medicare and Medicaid Services (CMS) issued its much anticipated final Medicare Advantage and Medicare Part D Drug Pricing Rule (CMS-4180-F). At this time, CMS has decided not to include much needed reforms of Direct and Indirect Remuneration (DIR) fee practices. Although CMS is not implementing this policy for 2020, the agency stated that it is continuing to carefully review submitted comments as it continues to consider policies that would lower prescription drug costs, address challenges that independent pharmacies face, and improve the quality of pharmacy care. Congress has also shown interest in reigning in abusive DIR fees with the introduction of the Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 803 and its Senate companion bill S. 988.
The Final Medicare Advantage and Medicare Part D Drug Pricing Rule (CMS-4180-F) can be found HERE.